Summary (tl;dr)

The American College of Cardiology (ACC) and the American Heart Association (AHA) have released a significant update to their guidelines for managing cholesterol and other blood lipids, aiming for earlier intervention and more personalized risk assessment to prevent heart disease.

Essential Background

The American College of Cardiology (ACC) and the American Heart Association (AHA) are leading professional organizations in the United States dedicated to cardiovascular health. They regularly publish evidence-based guidelines that serve as critical recommendations for healthcare providers on the prevention and treatment of various heart conditions, including the management of cholesterol. These guidelines are crucial as they influence medical practice and public health strategies to combat cardiovascular diseases. The new 2026 guideline replaces the previously established 2018 guideline on blood cholesterol management.

The Full Story

The ACC and AHA, along with nine other medical associations, have just issued their updated "2026 Guideline on the Management of Dyslipidemia," which focuses on abnormal levels of lipids like cholesterol and triglycerides. Released on March 13, 2026, this comprehensive guideline introduces several key changes. It emphasizes earlier intervention through lifestyle modifications, potentially starting in childhood, and the use of cholesterol-lowering medication when necessary. Notably, the new recommendations bring back specific LDL-C (low-density lipoprotein cholesterol, often called "bad" cholesterol) treatment goals, with lower targets for higher-risk groups.

The guideline also expands the use of certain diagnostic tools, recommending selective use of coronary artery calcium (CAC) scans to refine risk assessment, particularly for individuals with borderline or intermediate risk. Furthermore, it advises testing for lipoprotein(a) (Lp(a)) at least once in adulthood and selective apolipoprotein B (ApoB) measurement to improve risk stratification. A new cardiovascular disease risk calculator, PREVENT-ASCVD, is now recommended for primary prevention. These updates are designed to consolidate evidence-based recommendations into a single, comprehensive resource.

Why It Matters

These updated guidelines are significant because atherosclerotic cardiovascular disease (ASCVD), caused by fatty deposits in arteries, remains the leading cause of death globally. The emphasis on earlier and more aggressive management of cholesterol, including lifestyle changes and potentially medication, aims to reduce lifetime exposure to unhealthy lipids and lower the risk of heart attacks and strokes. For healthcare providers, the guidelines offer a consolidated and updated framework for assessing and treating dyslipidemia, incorporating new risk prediction tools and expanded testing options for personalized patient care. For patients, it means a more proactive approach to cholesterol management, with potentially lower cholesterol targets and additional screening options to better understand and mitigate their individual cardiovascular risk.

Geographic Location

• Dallas, Dallas County, Texas, United States (American Heart Association headquarters)
• Washington, D.C., District of Columbia, United States (American College of Cardiology headquarters)
• Virtual/Online (Joint publication of the guideline in JACC and Circulation journals)